European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

The Netherlands

Dear Sir/Madam,

RE: APOLLO premature termination

IRAS ID: 261164
Protocol Title: APOLLO: A Polatuzumab Vedotin containing Chemo-Immunotherapeutic regimen in patients with Diffuse Large B-Cell Lymphoma unsuitable for full dose R-CHOP Therapy**.**
Chief Investigator: Professor Nagesh Kalakonda
Sponsor name and address:
The Clatterbridge Cancer Centre NHS Foundation Trist
65 Pembroke Place
Liverpool
L78YA

Sponsor Protocol Code: **ML41135**
EudraCT Number: 2019-000842-36

The above study APOLLO was registered on EudraCT on 07/02/2019 and obtained MHRA approval from the UK competent authority on 30/12/2019.

The study was abandoned before recruiting any patients. This was due to due to the trial set-up being significantly delayed due to multiple factors and the trials centre identified escalated costs and shortfall in funding. A request to the funder for additional funds was denied and hence it was deemed that the trial cannot be initiated or proceed.

The trial did not secure sponsor greenlight and hence recruitment did not commence at any of the participating sites. No data or samples have been collected for evaluation of the safety and efficacy of the investigational medical product (IMP) polatuzumab vedotin as part of the APOLLO study protocol.

End of Trial Notification was submitted on 22/02/2023 with and end of trial date of 23/01/2023. Due to no patient recruitment no clinical trial report is going to be a prepared and uploaded.

If you require any further information and/or documentation, then please do not hesitate to contact us using the details below.

Many thanks,

Charlotte Rawcliffe
box SIGN 17V9R384-19W6YQ3Y

22 Jan 2024

Charlotte Rawcliife
Head of Trial Management
Liverpool Clinical Trials Centre